Free Access
Med Sci (Paris)
Volume 31, Number 1, Janvier 2015
Page(s) 98 - 104
Section M/S Revues
Published online 06 February 2015
  1. Debing Y, Jochmans D, Neyts J. Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol 2013 ; 3 : 217–224. [CrossRef] [PubMed] [Google Scholar]
  2. Antona D, Baudon C, Freymuth F, et al. La rougeole en France. Med Sci (Paris) 2012 ; 28 : 1003–1007. [CrossRef] [EDP Sciences] [Google Scholar]
  3. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010 ; 375 : 1545–1555. [CrossRef] [PubMed] [Google Scholar]
  4. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013 ; 11 : 836–848. [CrossRef] [PubMed] [Google Scholar]
  5. International ASSWGoHIVC, Deeks SG, Autran B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12 : 607–614. [CrossRef] [PubMed] [Google Scholar]
  6. Pockros PJ. Advances in newly developing therapy for chronic hepatitis C virus infection. Front Med 2014 ; 8 : 166–174. [CrossRef] [PubMed] [Google Scholar]
  7. Pol S.. Virus de l’hépatite C. 25 ans, la fin de l’histoire ?. Med Sci (Paris) 2013 ; 29 : 998–1003. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  8. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014 ; 508 : 402–405. [CrossRef] [PubMed] [Google Scholar]
  9. Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol 2011 ; 1 : 563–573. [CrossRef] [PubMed] [Google Scholar]
  10. Prussia A, Thepchatri P, Snyder JP, Plemper RK. Systematic approaches towards the development of host-directed antiviral therapeutics. Int J Mol Sci 2011 ; 12 : 4027–4052. [CrossRef] [PubMed] [Google Scholar]
  11. Es-Saad S, Tremblay N, Baril M, Lamarre D. Regulators of innate immunity as novel targets for panviral therapeutics. Curr Opin Virol 2012 ; 2 : 622–628. [CrossRef] [PubMed] [Google Scholar]
  12. Lucas-Hourani M, Munier-Lehmann H, Helynck O, et al. High-throughput screening for broad-spectrum chemical inhibitors of RNA viruses. J Vis Exp 2014 ; 87 : e51222. [Google Scholar]
  13. MacMicking JD. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol 2012 ; 12 : 367–382. [CrossRef] [PubMed] [Google Scholar]
  14. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011 ; 3 : 920–940. [CrossRef] [PubMed] [Google Scholar]
  15. Lucas-Hourani M, Dauzonne D, Jorda P, et al. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog 2013 ; 9 : e1003678. [CrossRef] [PubMed] [Google Scholar]
  16. Bedard KM, Wang ML, Proll SC, et al. Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses. J Virol 2012 ; 86 : 7334–7344. [CrossRef] [PubMed] [Google Scholar]
  17. Tai ZF, Zhang GL, Wang F. Identification of small molecule activators of the janus kinase/signal transducer and activator of transcription pathway using a cell-based screen. Biol Pharm Bull 2012 ; 35 : 65–71. [CrossRef] [PubMed] [Google Scholar]
  18. Patel DA, Patel AC, Nolan WC, et al. High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. PLoS One 2012 ; 7 : e36594. [CrossRef] [PubMed] [Google Scholar]
  19. Bonavia A, Franti M, Pusateri Keaney E, et al. Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci USA 2011 ; 108 : 6739–6744. [CrossRef] [Google Scholar]
  20. Wang QY, Bushell S, Qing M, et al. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 2011 ; 85 : 6548–6556. [CrossRef] [PubMed] [Google Scholar]
  21. Hoffmann HH, Kunz A, Simon VA, et al. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci USA 2011 ; 108 : 5777–5782. [CrossRef] [Google Scholar]
  22. Smee DF, Hurst BL, Day CW. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother 2012 ; 22 : 263–272. [CrossRef] [PubMed] [Google Scholar]
  23. Munier-Lehmann H, Vidalain PO, Tangy F, Janin YL. On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem 2013 ; 56 : 3148–3167. [CrossRef] [PubMed] [Google Scholar]
  24. Liu S, Neidhardt EA, Grossman TH, et al. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure 2000 ; 8 : 25–33. [CrossRef] [PubMed] [Google Scholar]
  25. Ortiz-Riano E, Ngo N, Devito S, et al. Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor. J Virol 2014 ; 88 : 878–889. [CrossRef] [PubMed] [Google Scholar]
  26. Marschall M, Niemann I, Kosulin K, et al. Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis. Antiviral Res 2013 ; 100 : 640–648. [CrossRef] [PubMed] [Google Scholar]
  27. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening Assays. J Biomol Screen 1999 ; 4 : 67–73. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.